<h4>Background</h4>Ponatinib (PON), an effective tyrosine kinase inhibitor for leukemias harboring the T315I mutation, is limited by severe cardiotoxicity, including myocardial infarction and heart failure. The gene discussed is PON1; the disease is heart failure.